Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00025935
Other study ID # 020021
Secondary ID 02-M-0021
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2002

Study information

Verified date January 3, 2024
Source National Institutes of Health Clinical Center (CC)
Contact Melissa A Brotman, Ph.D.
Phone (301) 435-6645
Email melissa.brotman@nih.gov
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study seeks to learn more about the symptoms of severe mood dysregulation in children and adolescents ages 7-17. Children and adolescents with severe mood dysregulation (SMD) display chronic anger, sadness, or irritability, as well as hyperarousal (such as insomnia, distractibility, hyperactivity) and extreme responses to frustration (such as frequent, severe temper tantrums). Researchers will describe the moods and behaviors of children with these symptoms and use specialized testing and brain imaging to learn about the brain changes associated with this disorder....


Description:

Objective: Irritability is a common and impairing clinical presentation in youth. Despite its significant public health impact, the clinical course and pathophysiology of irritability remains poorly understood. Chronic and severe irritability is the primary symptom of the new DSM-5 diagnosis, disruptive mood dysregulation disorder (DMDD), is an associated symptom of other pediatric disorders including Attention-Deficit/Hyperactivity Disorder (ADHD), and can be a clinical precursor to Major Depressive Disorder (MDD) and anxiety disorders. In addition, irritability is a trait distributed continuously in youth, thereby fitting well within the National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC) initiative. Clinically impairing irritability in children and adolescents began to gain more attention as interest grew in the diagnosis of pediatric bipolar disorder. Beginning in the 1990s, child psychiatry researchers suggested that while pediatric bipolar disorder can present with distinct episodes of mania or hypomania as in adults, the more typical pediatric presentation was chronic, severe irritability and hyperarousal symptoms. However, data collected under this protocol comprise a series of longitudinal, family, behavioral, and pathophysiological studies that differentiated classically defined episodic pediatric bipolar disorder from chronic irritability without distinct manic or hypomanic episodes. These findings are consistent with reports from other groups and meta-analyses. Among the several strands of research designed to differentiate pediatric bipolar disorder from chronic irritability, longitudinal studies provide the strongest evidence that these two phenotypes are distinct. Children with chronic irritability are at elevated risk for later depression, but not manic episodes. Thus, youth with MDD (with and without prior DMDD) are an important comparison group to explore, and we are examining the developmental trajectory, phenomenology, behavioral correlates, and underlying neural mechanisms of chronic irritability and MDD in youth. Further, because irritability and ADHD symptoms are highly comorbid in youth, participants with ADHD are an important comparison group in our work on irritability. The current translational model of irritability emphasizes the role of abnormal threat and reward processing, but also underlines the relevance of environmental factors in the emergence and maintenance of irritability. More precisely, it is assumed that irritable children experience environments, where rewards and punishments are inconsistently delivered leading to unintentional reinforcement of disruptive behavior through the parents. Reasons for this inconsistent parent behavior could be manifold spanning instrumental learning deficits and exaggerated responses to threat and frustrative non-reward in the parents themselves as well as lack of knowledge regarding learning principles and increased levels of stress . These factors might contribute to instrumental-learning deficits in the children increasing frequency and intensity of temper outbursts. Heightened levels of chronic irritability, another symptom of DMDD, might be more associated with features of the parent-child interaction. There is a rich literature within the framework of attachment theory showing that behavior of children with anxious-resistant insecure attachment is characterized by a general angry tone and is also associated with increased amygdala responses to negative social scenes. In addition, it was also shown that highly irritable infants are less sociable in terms of being less responsive and more fearful towards others and displaying an angry emotional tone in general as toddlers when they had been insecurely attached and more sociable when they had been securely attached. Adding another layer of complexity, it is also conceivable that inconsistent parent behavior diminishes parent s perceived trust-worthiness. This could be of relevance as recent studies showed that persons are less willing to delay rewards an action bound to increase levels of frustration - if their interaction partner is perceived as little reliable. The overall goal is to gain a clearer understanding of the environmental factors contributing to irritability in order to inform treatment and improve the outcome for children. As part of this overall goal, we plan to collect information on numerous environmental factors. First, we plan to investigate parents of youth with DMDD enrolled in this study and subthreshold DMDD enrolled in this study in order to determine clinical, behavioral, neuropsychological, neurophysiological and neuroanatomical features of the parents that contribute to the symptomatology in the children and adolescents. Further, we plan to examine parent-child interaction and its influence on irritability observed in the youth. Second, we plan to investigate the role of environmental stressors, such as the COVID-19 pandemic, on youth s irritability symptoms. Study population: There are 6 separate populations being studied in this protocol: 1. Children and adolescents between the ages of 7-17 years old who meet criteria for DMDD or subthreshold DMDD. 2. Parents of children and adolescents, who meet criteria for DMDD or subthreshold DMDD and are enrolled in 02-M-0021, and are 25 - 59 years old will be studied. 3. Healthy volunteer children and adolescents between the ages of 7-17 years old. 4. Healthy volunteer adults between the ages of 18-25 years old. 5. Children and adolescents between the ages of 12-17 years old who meet criteria for major depressive disorder (MDD). 6. Children and adolescents between ages of 8-17 years who meet criteria for attention-deficit/hyperactivity disorder (ADHD) who do not have a mood disorder. Design: For children and adolescents with full or subthreshold DMDD and/or MDD, this study is an outpatient characterization and longitudinal follow-along design. Once determined to be eligible, individuals come for an initial assessment, and then return at varying intervals until age 25 for clinical interviews, behavioral tasks, and structural and functional MRI. For healthy volunteer children, adults and parents of healthy volunteer children, this study is an outpatient cross-sectional study that includes clinical interviews, behavioral tasks, and structural and functional MRI. For all individuals, genetic material from saliva or blood is obtained under protocol 01-M-0254. Outcome measures: There are two primary outcome measures. First, this study will examine associations between irritability and clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables in individuals with full or subthreshold DMDD and/or MDD, ADHD, anxiety, and healthy volunteers. Second, this study will examine between-group differences in clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables in individuals with full or subthreshold DMDD and/or MDD, ADHD, anxiety, and healthy volunteers.


Recruitment information / eligibility

Status Recruiting
Enrollment 2350
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 7 Years to 60 Years
Eligibility - INCLUSION CRITERIA: 1. Inclusion criteria for children with DMDD, subthreshold DMDD: 1.1.1 Ages 7-17 at the time of recruitment; will be followed in the longitudinal component of the study until age 25. 1.1.2 Abnormal mood (specifically, anger, sadness, and/or irritability), present at least half of the day most days (or at least half the day at least one day per week for subthreshold), and of sufficient severity to be noticeable by people in the child s environment (e.g. parents, teachers, peers). 1.1.3 Compared to his/her peers, the child exhibits markedly increased reactivity to negative emotional stimuli that is manifest verbally or behaviorally. For example, the child responds to frustration with extended temper tantrums (inappropriate for age and/or precipitating event), verbal rages, and/or aggression toward people or property. Such events occur, on average, at least three times a week. For subthreshold DMDD such tantrums occur on average at least once per month. 1.1.4 The symptoms in # 1.1.2, and 1.1.3 above are currently present and have been present for at least 12 months without any symptom-free periods exceeding three months. 1.1.5 The onset of symptoms must be prior to age 10 years. 1.1.6 For DMDD the symptoms are severe in at least in one setting (e.g. violent outbursts, assaultiveness at home, school, or with peers) and at least mild (distractibility, intrusiveness) in a second setting. For subthreshold DMDD, there must be evidence of impairment causing distress to the child or to those around him/her in at least one setting. 2. Parents of children and adolescents with DMDD or subthreshold DMDD enrolled in 02-M-0021 2.1.1. Are capable of performing behavioral tasks and/or scanning. 2.1.2. Speaks English 3. Healthy Volunteer (Control) Children 3.1.1. Control subjects will be group matched to the patients. 3.1.2. Have an identified primary care physician. 3.1.3. Speaks English 4. Healthy Volunteer Adults 4.1.1 Control subjects will be group matched to the patients. 4.1.2. They will have normal physical and neurological examinations by history or checklist 4.1.3. Have an identified primary care physician. 4.1.4 Speaks English 5. Children with Major Depressive Disorder (MDD) Inclusion criteria (all must be met): 5.1.1 Ages 11-17 at the time of recruitment; will be followed in the longitudinal component of the study until age 25. 5.1.2. DSM-IV or DSM-5 Major Depressive Disorder 5.1.2.1 Five or more of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. 5.1.2.1.1 Depressed mood most of the day, nearly every day, as indicated by either subjective report (e.g., feeling sad, blue, down in the dumps, or empty) or observation made by others (e.g., appears tearful or about to cry). (In children and adolescents, this may present as an irritable or cranky, rather than sad, mood.) 5.1.2.1.2 Markedly diminished interest or pleasure in all, or almost all, activities every day, such as no interest in hobbies, sports, or other things the person used to enjoy doing. 5.1.2.1.3. Significant weight loss when not dieting or weight gain (e.g., a change of more than 5 percent of body weight in a month), or decrease or increase in appetite nearly every day. 5.1.2.1.4. Insomnia (inability to get to sleep or difficulty staying asleep) or hypersomnia (sleeping too much) nearly every day 5.1.2.1.5. Psychomotor agitation (e.g., restlessness, inability to sit still, pacing, pulling at clothes or clothes) or retardation (e.g., slowed speech, movements, quiet talking) nearly every day 5.1.2.1.6. Fatigue, tiredness, or loss of energy nearly every day (e.g., even the smallest tasks, like dressing or washing, seem difficult to do and take longer than usual). 5.1.2.1.7. Feelings of worthlessness or excessive or inappropriate guilt nearly every day (e.g., ruminating over minor past failings). 5.1.2.1.8. Diminished ability to think or concentrate, or indecisiveness, nearly every day (e.g. appears easily distracted, complains of memory difficulties). 5.1.2.1.9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideas without a specific plan, or a suicide attempt or a specific plan for committing suicide 5.1.2.1.10 Symptoms cause clinically significant distress or impairment in social, occupational/academic, or other important areas of functioning. 5.1.2.1.11. The episode is not attributable to the physiological effects of a substance or to another medical condition. 5.1.3. Youth with MDD who are continuing in research as adults must also be receiving psychiatric care for their MDD, if it is ongoing 6. Children with Attention-Deficit/Hyperactivity Disorder (ADHD) 6.1.1. Age 8-17 6.1.2. Currently meets DSM-IV or DSM-5 criteria for ADHD 6.1.3. Subjects with other primary psychiatric disorders including anxiety disorders, dysthymic disorder, past major depression, oppositional defiant disorder, tic disorders, and the learning, communication, and elimination disorders may be accepted 6.1.4. Have an identified primary care physician. 6.1.5. Speaks English EXCLUSION CRITERIA: 1.3 Exclusion criteria for those with DMDD: 1.3.1 The individual exhibits any of these cardinal bipolar symptoms: 1.3.1.1 Elevated or expansive mood 1.3.1.2 Grandiosity or inflated self-esteem 1.3.1.3 Decreased need for sleep 1.3.1.4 Increase in goal-directed activity (this can result in the excessive involvement in pleasurable activities that have a high potential for painful consequences) 1.3.1.5. Has BD symptoms in distinct periods lasting more than 1 day. 1.3.2. Meets criteria for schizophrenia, schizophreniform disorder, schizoaffective illness, PDD, or PTSD. 1.3.3. IQ< 70 1.3.4. The symptoms are due to the direct physiological effects of a drug of abuse, or to a general medical or neurological condition. 1.3.5. Currently pregnant or lactating 1.3.6. Meets criteria for alcohol or substance abuse with the last three months 1.3.7. NIMH IRP Employees/staff and immediate family members will be excluded from the study per NIMH policy. 2. Exclusion of parents of children and adolescents with DMDD or subthreshold DMDD 2.1Are an NIMH IRP Employees/staff 2.2Have an I.Q. < 70 2.3 Have any serious medical condition or condition that interferes with participation 3.2 Healthy Volunteer Exclusion criteria: 3.2.1. I.Q. < 70; 3.2.2. Any serious medical condition or condition that interferes with fMRI scanning pregnant or lactating; 3.2.3. Past or current diagnosis of any anxiety disorder (panic disorder, GAD, Separation Anxiety Disorder, Social Phobia), mood disorder (manic or hypomanic episode, major depression), OCD, PTSD, Conduct Disorder, psychosis, current suicidal ideation, Tourette Disorder, Autism Spectrum Disorder or ADHD. 3.2.4. Substance abuse within two months prior to study participation or present substance abuse 3.2.5. History of sexual abuse. 3.2.6. Parent or sibling with Bipolar Disorder, recurrent MDD, or any disorder with psychosis. 3.2.7. NIMH IRP Employees/staff and immediate family members will be excluded from the study per NIMH policy. 4.2 Healthy Volunteer Adult Exclusion criteria: 4.2.1. IQ< 70 4.2.2. Pregnant 4.2.3. Any past or current history of Bipolar Disorder (any manic or hypomanic episode), recurrent MDD, or any disorder with psychosis 4.3.3 NIMH IRP Employees/staff and immediate family members will be excluded from the study per NIMH policy. 5.3 Exclusion criteria for those with MDD: 5.3.1 The individual exhibits any of these cardinal bipolar symptoms: 5.3.1.1 Elevated or expansive mood 5.3.1.2 Grandiosity or inflated self-esteem 5.3.1.3 Decreased need for sleep 5.3.1.4 Increase in goal-directed activity (this can result in the excessive involvement in pleasurable activities that have a high potential for painful consequences) 5.3.1.5. Has BD symptoms in distinct periods lasting more than 1 day. 5.3.2. Meets criteria for schizophrenia, schizophreniform disorder, schizoaffective illness, PDD, or PTSD. 5.3.3. IQ< 70 5.3.4. The symptoms are due to the direct physiological effects of a drug of abuse, or to a general medical or neurological condition. 5.3.5. Currently pregnant or lactating 5.3.6. Meets criteria for alcohol or substance abuse with the last three months 5.3.7. NIMH IRP Employees/staff and immediate family members will be excluded from the study per NIMH policy. 6.2. Exclusion criteria for those with ADHD: 6.2.1. IQ<70 6.2.2. Pregnancy (excludes for scanning only) 6.2.3. Ongoing medical illness or neurological disorder other than ADHD 6.2.4.<TAB>Any condition that would interfere with the participants ability to perform research tasks 6.2.5. Current Major Depression 6.2.6. Any past or present manic or hypomanic episode For all groups: NIMH employees are excluded

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lithium


Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To examine between-group differences in clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables Individuals with full or subthreshold DMDD and/or MDD, ADHD, anxiety (see protocol 00-M-0192), and healthy volunteers (see protocol 00-M-0198). 20 years
Primary To examine associations between irritability and clinical, behavioral, genetic, neuroanatomical, and neurophysiological variables Individuals with full or subthreshold DMDD and/or MDD, ADHD, anxiety (see protocol 00-M-0192), and healthy volunteers (see protocol 00-M-0198). 20 years
See also
  Status Clinical Trial Phase
Completed NCT00001919 - Neuroimaging of St. John's Wort-Induced Changes of Serotonin Metabolism in Normal Subjects N/A
Completed NCT00026832 - Examination of Brain Serotonin Receptors in Patients With Mood Disorders
Completed NCT01951508 - Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study Phase 0
Terminated NCT01830088 - Family Based Treatment of Depressed Adolescents (AHUS) N/A
Completed NCT01269710 - Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study N/A
Completed NCT00001146 - Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial Phase 2
Completed NCT00001170 - Study of the Psychological Development of Children of Parents With and Without Affective Disorders N/A
Completed NCT00001192 - Neuropsychological Evaluation of Psychiatric and Neurological Patients N/A
Completed NCT02189057 - A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression N/A
Completed NCT01473550 - Mental Health Engagement Network (MHEN) N/A
Completed NCT00990067 - Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) Phase 1
Completed NCT00794040 - A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation Phase 2
Completed NCT02819986 - Effectiveness of Using the Progressive Goal Attainment Program in Anxiety and Mood Disorders N/A
Completed NCT03538860 - Validation of an Automated Online Language Interpreting Tool - Phase Two. N/A
Completed NCT00016731 - Adolescence, Puberty, and Emotion Regulation
Completed NCT02721316 - Outpatient Nurse Monitoring Under the Prevention of Recurrent Suicidal N/A
Recruiting NCT02443636 - The Canadian Depression Research and Intervention Network (CDRIN) Maritimes Registry
Terminated NCT01493323 - Functional Imaging of Psychic Pain N/A
Completed NCT00699218 - A Pilot Study on Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Bipolar Depression N/A
Completed NCT00001654 - The Role of Emotion in the Development of Psychopathology N/A